Please try another search
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulising crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating breast cancer; and GB492, a stimulator of interferon genes in combination with GB226 to treat solid tumors and is under Phase 1/2 clinical trial. It also develops GB226, which is in phase III clinical trial to treat 2L+ Cervical Cancer; phase II to treat ASPS and r/r PMBCL; and is in phase I to treat 2L/3L+ EGFR+ NSCLC and 2L+ mCRC. In addition, the company develops GB261, which is in phase I/II clinical trial to treat NHL; and GB263T to treat NSCLC and is in phase I/II clinical trial. Further, it develops GB221, which is in phase III clinical trial for the treatment of HER2 + 1L/2L+ mBC; GB223, which is in phase I clinical trial to treat GCTB and PMO; GB241, which is in phase III clinical trial to treat 1L DLBCL; and GB251 which is in phase I clinical trial to treat HER2 + 1L/2L+ mBC. Additionally, the company’s product candidates under clinical trials, including GB262, GB264, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Honghao Zhou | 84 | 2020 | Independent Non-Executive Director |
Zhijian Chen | - | 2021 | Chairman of Scientific Advisory Board |
John F. Seymour | - | 2021 | Member of Scientific Advisory Board |
Wen Chen | 56 | 2020 | Independent Non-Executive Director |
Alex A. Adjei | 68 | 2021 | Member of Scientific Advisory Board |
Feng Guo | 54 | 2020 | CEO & Chairman |
David J. Kerr | - | 2021 | Member of Scientific Advisory Board |
Yangxin Fu | - | 2021 | Member of Scientific Advisory Board |
Dong Lyu | 48 | 2021 | Non Executive Director |
Yi Liu | 34 | 2022 | Non-Executive Director |
Edwin Fung | 59 | 2020 | Independent Non-Executive Director |
Leonard B. Saltz | - | 2021 | Member of Scientific Advisory Board |
John R. Zalcberg | - | 2021 | Member of Scientific Advisory Board |
Tieming Yu | 42 | 2024 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review